terça-feira, 6 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 26, 2025

2025: The year the Big 3 backed away from EVs

View original at finance.yahoo.com
2025: The year the Big 3 backed away from EVs The last couple of weeks of the year are typically a slow time in the auto business, at least on the corporate front…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The execution at GM has been way more consistent, which is the reason why their margins have been so much larger compared to Ford over the past seven, eight years. I think GM has been [more consistent in execution] under Mary Barra. We've seen as the tables turn, more decisive steps, more control over all the things that the industry throws at them, whether it's supply chain shocks from bottlenecks that emerge, labor union negotiations, you name it.

    80% confidence
  • I wouldn't be surprised if more charges were to happen, and that's only because after Q3 when they put out the $1.6 billion charge announcement, there was a pretty clear statement in their filing which said there could be more material announcements related to program cancelations, supplier charges, etc., very similar to what Ford announced

    80% confidence
  • We're going to do the right hybrids that we think are important for our portfolio, but I also think we have a very strong EV portfolio and a very strong internal combustion [portfolio]. We're going to be positioned to compete well, but also be good stewards of our owners' capital and how we deploy R&D dollars.

    80% confidence
  • Stellantis has launched new ICE product in the US to capitalize on the trend of prolonged combustion engine life and should benefit from a mix skew to ICE particularly in the US

    80% confidence
  • There's no question that the demand environment is going to be challenging. Companies generally expect EV adoption to hit about 5% to 7% of new vehicle sales over the very near term. But our message over the next couple of years is don't sleep on the US EV market.

    80% confidence
  • Ford could conceivably be vulnerable to any upside from EV demand, should it arise

    80% confidence
  • After over-investing in luxury EVs and electric trucks, automakers are now pivoting toward the sub-$35,000 segment, think revamped Bolts and Leafs, to keep EV adoption alive

    80% confidence
  • Overall, ICE technology will be around for longer which is positive for mix of OEMs but at the same time requires additional investments to keep the technology up to date and has caused write-offs on EV model lines. We find that others like GM and Ford are increasingly promoting the narrative around flexible manufacturing.

    80% confidence
  • We view it as a decisive, strategic reset. Historically, Ford's been a little slow to act on very important strategic items in terms of cutting losses early

    80% confidence
  • We think that for Stellantis to get back towards levels of profitability we see at GM, it's going to take a while

    80% confidence
  • It does give them long-term flexibility and near term we see the path towards less losses, because they're going to be having less underutilized EV assets

    80% confidence
  • They still have a wide portfolio and enough capacity to adjust to market demand, and they'll have, of course, new technologies as well

    80% confidence
  • We can't allocate money for things that will not make money. As much as I love those products, the customers in the US were not going to pay for them. And that was the end of that.

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com